Up to 58% of the world's adult population is predicted to be overweight or obese by 2030 (ref. 1). Obesity predisposes to numerous diseases, including heart disease, type 2 diabetes and cancer; thus, understanding how body weight is regulated is of major scientific, health and economic importance. Genome-wide association studies have revealed that SNPs (including rs9939609, rs17817449, rs3751812, rs1421085 and rs9930506) in intron 1 of FTO are associated with an increased risk of obesity [2] [3] [4] [5] . Approximately 16% of individuals of European descent are homozygous for the at-risk allele, weighing on average ~3 kg more than controls 4, 5 . Evidence suggests that these individuals also exhibit increased food intake [6] [7] [8] [9] [10] [11] [12] [13] .
Up to 58% of the world's adult population is predicted to be overweight or obese by 2030 (ref. 1) . Obesity predisposes to numerous diseases, including heart disease, type 2 diabetes and cancer; thus, understanding how body weight is regulated is of major scientific, health and economic importance. Genome-wide association studies have revealed that SNPs (including rs9939609, rs17817449, rs3751812, rs1421085 and rs9930506) in intron 1 of FTO are associated with an increased risk of obesity [2] [3] [4] [5] . Approximately 16% of individuals of European descent are homozygous for the at-risk allele, weighing on average ~3 kg more than controls 4, 5 . Evidence suggests that these individuals also exhibit increased food intake [6] [7] [8] [9] [10] [11] [12] [13] .
FTO is an AlkB-like 2-oxoglutarate-dependent nucleic acid demethylase [14] [15] [16] with a strong preference for 3-methylthymidine and 3-methyluracil in single-stranded DNA and RNA, respectively, owing to unique structural features 17 . A human FTO mutation (resulting in the p.Arg316Gln alteration) that inhibits catalytic activity results in an autosomal recessive lethal syndrome 15 .
Mice lacking Fto show increased postnatal lethality, postnatal growth retardation, a reduced amount of adipose tissue and spontaneous locomotor activity, increased energy expenditure, and relative hyperphagia 18 . A dominant mutation (resulting in p.Ile367Phe) in the mouse Fto gene that reduces its DNA demethylation activity also results in reduced fat mass 19 . Taken together, these studies in the mouse suggest that loss of Fto expression and/or FTO function protects against obesity.
FTO is ubiquitously expressed in the embryo and adult 4 . High Fto mRNA levels are observed in the brain, including the cerebellum, hippocampus and hypothalamus 14, 20, 21 . In humans, FTO mRNA levels are higher in males and are positively correlated with body mass index (BMI) in adipose tissue 22 (although, see ref. 23 for an exception). FTO mRNA expression is also greater in subcutaneous adipose tissue (SAT) [24] [25] [26] of obese individuals compared to that of controls.
The association between brain Fto mRNA levels and food intake is controversial. Both increases (in rat 27 in the hypothalamus) and decreases (in mice 14, 28 in the arcuate nucleus) in Fto mRNA levels have been reported to be linked to fasting. Direct manipulation of Fto RNA levels in the arcuate nucleus of rats by adenoviral infection of Fto or by small interfering RNA (siRNA) against Fto influences food intake; reduction in Fto expression leads to increased food intake and enhanced expression leads to decreased food intake 29 . Notably, mice with the p.Ile367Phe alteration did not show detectable altered food intake 19 .
Taken together, these data demonstrate that the role of FTO in food intake in either humans or mice is ambiguous. Many 6, 8, 9, 11 , but not all 12, 30, 31 , studies suggest that food intake is greater in humans who carry at-risk FTO SNPs. A confounder in obesity studies is that increased body mass requires increased energy expenditure for locomotion and potentially increased energy intake to match, making it difficult to determine the cause and effect of obesity phenotypes. The effects of loss of FTO function in rodents also remains unclear; deletion of the gene is reported to cause relative hyperphagia 18 , whereas reduced demethylation activity had no effect on food intake 19 . This raises the question of whether increased FTO expression alters food intake and body weight in humans.
There is now the first evidence that primary transcripts containing an at-risk A allele at rs9939609 are more abundant than those with the T allele in blood and fibroblast RNA samples from several normal-weight (BMI 18.5-25.0 kg m −2 ) individuals, suggesting that increased expression of FTO may be correlated with obesity 32 . To test Overexpression of Fto leads to increased food intake and results in obesity this hypothesis, we compared the effects of different copy numbers of the Fto gene using mouse models. Our data provide evidence that enhanced expression of Fto causes obesity.
RESULTS
To test the hypothesis that upregulation of FTO expression causes obesity, we generated mice that globally expressed either one or two additional copies of the Fto gene ( Supplementary Fig. 1 and Online Methods). We refer to these as FTO-3 and FTO-4 mice (as they have either three or four copies of Fto in total), and we refer to wildtype mice as FTO-2 mice.
Fto overexpression
Using quantitative RT-PCR (qRT-PCR) we showed increased Fto mRNA expression in multiple tissues of mice carrying additional copies of the Fto gene (Fig. 1a) . In FTO-3 mice this increase was largest in the pancreas (~8-fold), whereas in FTO-4 mice, we found the greatest increase in expression (~11-fold) to be in skeletal muscle, followed by the pancreas. We used protein blot analysis to confirm that FTO protein was overexpressed in skeletal muscle and liver (Fig. 1b) ; this increase ranged from 1.9-fold in skeletal muscle of FTO-3 mice to 2.3-fold in FTO-4 mouse liver. We also confirmed expression of the EGFP reporter by RT-PCR (Fig. 1c) .
Dose-dependent Fto expression affects body weight
Mice carrying additional copies of the Fto gene exhibited increased body weight (Fig. 2) . On a standard diet, female FTO-3 mice diverged from the wild type at ~5 weeks, becoming 11% ± 3% (s.e.m.) heavier than FTO-2 littermates by 20 weeks of age ( Fig. 2a and Fig. 3a) . Female FTO-4 mice showed earlier divergence from the wild type (4 weeks of age; Fig. 2a ) and were 22% ± 4% heavier at 20 weeks (Fig. 3a) . We obtained similar results for male FTO-3 and FTO-4 mice, although the increase in weight was slightly less than for female mice; by 20 weeks of age, male FTO-3 and FTO-4 mice were 7% ± 2% and 10% ± 1% heavier, respectively, than their FTO-2 littermates ( Fig. 2c and Fig. 3a) .
In all genotypes, a high-fat diet (HFD) led to increased body weight. However, the effect was greater in mice overexpressing Fto (Fig. 2b,d ). After 20 weeks, female FTO-3 and FTO-4 mice were 9% ± 2% and 18% ± 6% heavier, respectively, than FTO-2 mice (Fig. 2b  and Fig. 3a) . Male mice also showed an increased body weight (7% ± 2% for FTO-3 and 13% ± 3% for FTO-4 mice) ( Fig. 2d and Fig. 3a) . Body length was not different from the wild type in FTO-3 and FTO-4 mice (data not shown).
Dose-dependent expression of Fto affects fat mass
Mice overexpressing Fto showed increased fat mass ( Fig. 3b and Supplementary Fig. 2 ). Twenty-week-old female FTO-3 mice on a standard diet displayed a 42% ± 8% increase in fat mass, and FTO-4 mice displayed a 85% ± 9.5% increase in fat mass compared to FTO-2 control mice (Fig. 3b) . Male FTO-3 and FTO-4 mice showed similar increases in fat mass (Fig. 3b) . A greater increase in fat mass was seen on a high-fat diet, with similar increases in FTO-3 and FTO-4 mice relative to wild-type mice. This was again particularly pronounced in A r t i c l e s female mice, where fat mass was 18% ± 7% (FTO-3) and 68% ± 21% (FTO-4) greater than that of the wild type at 20 weeks (Fig. 3b) . In male mice, fat mass was also increased, being 24% ± 7% (FTO-3) and 43% ± 10% (FTO-4) greater than wild type (Fig. 3b) .
We observed similar correlations between Fto copy number and the weight of dissected fat pads. Thus, epigonadal and abdominal white adipose tissues (WATs) were heavier in female FTO-3 and FTO-4 mice than in FTO-2 mice (Fig. 3c,d ). We found similar results in male mice, except that epigonadal WAT was not increased in FTO-3 mice. High-fat feeding further exacerbated the dose-dependent effect of Fto overexpression on epigonadal and abdominal WAT in both male and female mice (Fig. 3c,d ). Hematoxylin and eosin histological analysis of epigonadal WAT ( Supplementary Fig. 3a ) showed an increase in adipocyte size at 20 weeks of age on both standard and high-fat diets in females and on a high-fat diet in males when assessed quantitatively through the adipocyte area (Fig. 3e) .
Lean mass was affected to a lesser extent when Fto was overexpressed, but female FTO-4 mice showed a 21% ± 9% increase in lean mass on a standard diet (Fig. 3f) . We found no significant difference in lean mass between FTO-2 and FTO-3 or FTO-4 mice on a high-fat diet ( Fig. 3f and Supplementary Fig. 2b,d ).
Regression analysis showed that mice overexpressing Fto have a different body composition compared to wild-type mice, showing a higher fat-to-lean tissue mass ratio (Supplementary Fig. 2 ).
Fto overexpression increases food intake
Many human studies have suggested that individuals carrying the at-risk FTO allele exhibit increased energy intake [6] [7] [8] [9] [10] [11] 13 . FTO-3 and FTO-4 mice on both standard and high-fat diets consumed more than FTO-2 mice at 10 weeks and at 19 weeks of age (Supplementary Fig. 3b ). The relative increase in food intake displayed by FTO-3 and FTO-4 mice compared to their wild-type littermates was even greater on a high-fat diet (Supplementary Fig. 3b ). This was maintained when food intake was normalized to body weight for FTO-3 and FTO-4 mice, with the exception of FTO-4 female mice on a standard diet, in which this increase in food intake was reduced to a trend (Fig. 4a) .
We confirmed these differences by regression analysis against body weight at 10 weeks, which showed increased food intake at all body weights for FTO-3 and FTO-4 mice (Supplementary Fig. 4) . At 20 weeks, a similar pattern was evident for males ( Supplementary  Fig. 5a,b) . Further, in 20-week-old FTO-4 males, food intake was elevated regardless of lean mass, fat mass (a trend on a standard diet, significant (P < 0.05) on a high-fat diet) or body composition (defined as the fat mass/lean mass (FM/LM) ratio; Supplementary  Fig. 5 ). These trends were less clear in females ( Supplementary  Fig. 6 and Supplementary Note).
As food intake is under endocrine and neuronal control and is influenced by leptin, we measured plasma leptin levels. At 8 weeks of age, circulating leptin levels after a 16-h overnight fast, either as raw data (data not shown) or corrected for body weight, were significantly lower in male and female FTO-4 mice than in FTO-2 mice, whether mice were maintained on a standard or high-fat diet (Fig. 4b) . This was largely confirmed by regression analysis against body weight (Supplementary Fig. 7a,b and Supplementary Fig. 8a,b) .
There was no significant difference in circulating leptin at 20 weeks of age either as raw data (data not shown) or corrected for fat mass, with the exception of FTO-3 males on a standard diet, which showed a significant increase in relative leptin levels (with a trend for an increase (P = 0.07) observed for FTO-4 males ( Supplementary  Fig. 3c, Supplementary Fig. 7c and Supplementary Fig. 8c)) . Regression analysis showed a clear positive correlation between leptin levels and fat mass in mice on a high-fat diet, explaining 76% (P = 0.0009) and 44% (P = 0.0018) of the variation in leptin for FTO-4 females and males, respectively ( Supplementary Fig. 7d and Supplementary Fig. 8d) . Consistent with the elevated circulating leptin, leptin mRNA expression was higher in epigonadal and subcutaneous WAT but was reduced in abdominal WAT of 20-week-old FTO-4 mice (Fig. 4c) .
Hypothalamic expression of Agrp, which encodes agouti-related protein, was elevated in fasting in 20-week-old FTO-4 male mice, but Npy (encoding neuropeptide Y) and Pomc (encoding proopiomelanocortin) levels were unaffected (Fig. 4d) .
Fto and alterations in energy expenditure
Previous studies with Fto knockout 18 and Fto p.Ile367Phe mutant mice 19 suggested that an increased metabolic rate might underlie their lean phenotype. We therefore used indirect calorimetry to assess metabolic rate in 18-week-old mice.
FTO-4 mice showed a significant increase in energy expenditure (heat, kcal h −1 ) on a standard diet during both light and dark periods, but we observed no other differences (Fig. 5a,b) . We then carried out multiple regression analysis for energy expenditure to assess the effect of potential explanatory variables (weight, lean mass, fat mass, sex, genotype and diet) using an additive linear model (Supplementary Table 1 ). We identified lean body mass (P = 0.0446) and high-fat diet (P = 4.2 × 10 −7 ) as predictors. We then used a model that automatically selected relevant variables, identifying weight (P = 0.0077), lean mass (P = 0.0003) and high-fat diet (P = 6.05 × 10 −8 ) as the main predictor of energy expenditure (adjusted r 2 correlation coefficient 0.441, P ≤ 2.2 × 10 −16 ). We confirmed these results using a robust fit linear model (data not shown). When tested alone, genotype was not a predictor of energy expenditure (data not shown).
There was no significant change in respiratory exchange ratio (RER) for FTO-3 or FTO-4 mice on either a standard or high-fat diet (data not shown). 
A r t i c l e s
Fto has no effect on activity or circadian period To assess whether reduced locomotor activity contributes to the obese phenotype of mice overexpressing Fto, we measured activity at 12 weeks of age by wheel running. We found no significant difference in wheel running during a 7-d period in either female or male FTO-3 or FTO-4 mice compared to FTO-2 mice (Fig. 5c) . There was also no difference in the length of wheel-running time during circadian challenges, including a shift to constant darkness or constant light, in mice overexpressing FTO compared to their wild-type littermates ( Supplementary Fig. 9a-d ).
An open-field anxiety paradigm was used to test a combination of locomotor activity, exploratory drive and other aspects of anxiety at 10 weeks of age. Female FTO-3 and FTO-4 mice showed no difference in total activity, as determined by the distance moved during the period (Supplementary Fig. 9e ), but female FTO-4 mice spent less time in the center of the open field, suggesting that they may be more anxious (Supplementary Fig. 9 f-h) . We observed no significant phenotype in male FTO-3 and FTO-4 mice (data not shown). Following 4 weeks of access to running wheels and the same light and dark regime, FTO-3 and FTO-4 mice showed increased body mass and fat mass at 12 weeks of age consistent with the phenotype observed at 20 weeks of age (Supplementary Table 2) .
Dose-dependent effect of Fto expression on glucose tolerance
We assessed glucose homeostasis at 12 weeks of age with a 120-min intraperitoneal glucose tolerance test (IPGTT) and examined the mice again at 16 weeks of age with a 30-min IPGTT (data not shown). We quantified glucose tolerance by measuring the area under the curve (AUC) relating plasma glucose levels to time. We observed no significant difference in AUC at 12 weeks between mice expressing different numbers of the Fto gene fed a standard diet (Fig. 6a) . Notably, when challenged with a high-fat diet, FTO-4 mice exhibited a reduction in glucose tolerance compared to wild-type mice, as shown by an increase in glucose AUC at 12 weeks (Fig. 6a) and at 16 weeks (Fig. 6b) .
Plasma insulin levels were unchanged at 8 weeks (fasting), 16 weeks (over a 30-min IPGTT) and 20 weeks (fasting) of age in male and female FTO-3 and FTO-4 mice on a standard diet (data not shown). However, male FTO-4 mice on a high-fat diet had elevated fasting insulin at 16 weeks of age (1.05 μg l −1 ± 0.22 μg l −1 compared to 0.64 μg l −1 ± 0.09 μg l −1 for wild type, P = 0.025). Female FTO-3 and FTO-4 mice had lower adiponectin levels than wild-type mice on a high-fat diet but not on a standard diet (Fig. 6c) , whereas the reverse was found for male mice (Fig. 6c) .
Fto overexpression alters plasma biochemistry
Plasma biochemistry measured in 20-week-old female mice is shown in Table 1 . Circulating plasma levels of triglycerides, free fatty acids (FFA) and high-density lipoprotein (HDL) cholesterol were significantly greater in FTO-3 and FTO-4 mice than in FTO-2 mice, but LDL cholesterol was reduced. We assessed liver function by measuring alkaline phosphatase (ALP), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. FTO-4 mice exhibited significantly increased ALT and lower albumin levels ( Table 1) . Creatine kinase was increased in FTO-3 and FTO-4 mice on standard and high-fat diets. We found no significant differences in males (data not shown).
DISCUSSION
Our data show that FTO is directly involved in the regulation of energy intake and metabolism in mice, and that enhanced expression of Fto leads to increased food intake and obesity.
Overexpression of Fto caused a dose-dependent increase in body weight and fat mass. The increase in weight of mice overexpressing Fto seems to be largely due to an increase in fat mass, as it is for humans carrying the at-risk allele 4, 33 . On a high-fat diet, female FTO-4 mice were 18% heavier, and FTO-3 mice were 9%, heavier than controls; on a standard diet, these mice were 22% heavier and 11% heavier, respectively. In comparison, humans carrying two at-risk alleles (for example, the rs9939609 A allele) are on average ~3.4% heavier (assuming an average adult body weight of 90 kg) than those carrying the low-risk alleles. Thus, FTO activity and expression in our mice is likely to be greater than in at-risk humans, enabling the phenotype to be dissected more easily.
Previous work showed that increased body mass in rs9939609 A allele carriers manifests during childhood 4 . Likewise, in FTO-4 mice, the increase in body weight was present early, being significantly different from that of the wild type at 4 weeks of age on a standard diet.
Overexpression of Fto led to a marked increase in food intake. This was observed on both standard and high-fat diets and at both 10 weeks and 19 weeks of age. We conclude that the increase in food intake contributes to the increased fat mass and body weight of FTO-3 and FTO-4 mice. Regression analysis at 20 weeks showed that food intake in male FTO-4 mice was elevated regardless of body weight, lean mass, fat mass or body composition (FM/LM). Mice overexpressing Fto reduced their food intake on a high-fat diet, relative to the standard diet, indicating that their energy intake was still regulated but that increased Fto expression had shifted the set point to a higher level. Most studies in humans report that at-risk SNPs enhance energy intake [6] [7] [8] [9] 11 , with some other studies finding no evidence of any effect on food intake 12, 30, 31 . Manipulation of Fto levels in the arcuate nucleus using adenoviral technology decreased food intake, in contrast to our observations 29 . However, in the Fto overexpression mice used in this study, other tissues may also influence food intake, such as additional brain regions, the gut and adipose tissue. Leptin, a hormone released from adipocytes that acts in the brain, is a potent regulator of food intake. We observed a reduction in circulating leptin levels at 8 weeks of age in mice overexpressing Fto, with the greatest reduction seen in FTO-4 mice. It is therefore possible that the hyperphagia of FTO-3 and FTO-4 mice is due to an FTO-dependent reduction in leptin concentration. However, we did not observe these differences in 20-week-old mice, and leptin levels correlated well with the increased fat mass. In human population studies, individuals with the FTO at-risk allele showed increased plasma leptin 31, 34 , but this effect disappeared when adjusted for BMI 34 , suggesting that this is a result of increased adiposity.
Multivariate regression analysis in the mice used in this study indicates that the most significant predictor of energy expenditure is a high-fat diet. The high-fat diet may increase body weight, which subsequently requires greater energy expenditure for physical activity (Fig. 5a,b) . Other significant determinants of energy expenditure were lean mass and weight. Notably, we did not detect genotype or sex effects in this global analysis of energy expenditure determinants. We conclude that, in these mouse models, energy expenditure is not a major determinant of the obese phenotype. Although humans carrying the FTO at-risk allele exhibited increased resting energy expenditure 31, 35, 36 , this difference was abolished when adjusted for fat mass (or lean body mass) 31, 35, 36 .
We found no effect of Fto copy number on spontaneous locomotor activity in mice. Similarly, in humans, there is no association between FTO risk alleles and the extent of leisure time physical activity 35, 37 (although physical activity may modify the effect of the FTO risk allele, as BMI was attenuated in high physical activity groups 38 ).
Obesity strongly increases the risk of type 2 diabetes. Consistent with this, FTO-4 mice showed marked glucose intolerance on a highfat diet.
The ubiquitous unregulated overexpression in our mice does not necessarily recapitulate normal expression patterns, although FTO is expressed ubiquitously 4, 14 . The functional consequences of the human risk alleles are likely to be more restricted than our promiscuous allele. Our analysis was carried out after the body weight had already diverged and could potentially be confounded by these changes.
We show that increased expression of Fto leads to increased fat mass and obesity through hyperphagia. These data suggest that the at-risk SNPs in the human FTO gene may enhance the expression and/or activity of FTO. Our data further suggest that anti-obesity drugs targeted to FTO should be designed to reduce FTO expression or activity and predict that their effects in vivo will largely act by reducing appetite.
URLs. Standardized protocols for EMPReSS, http://empress.har.mrc. ac.uk/; R, http://www.r-project.org/.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
